Alluvi, previously BI 4744, offers a notable breakthrough in weight control therapy. This dual activator targeting both glucagon-like peptide-1 and GIP receptors demonstrates impressive efficacy in patient trials, https://alluvi-research.co.uk/product/alluvi-retatrutide-40mg-rd-only/